Table 1.
Inorganic nanocarriers for drug delivery.
| Inorganic Carrier | Drug Loaded | Purpose | References |
|---|---|---|---|
| CaP | Docetaxel | Breast, lung, and ovarian cancer. | [8] |
| CaP, dopamine nanographene oxide (NGO) | Methotrexate | Anti-rheumatic drug, breast adenocarcinoma. | [38] |
| Heparin/CaCo/CaP | Doxorubicin hydrochloride | Breast, lung, bladder, stomach, and ovarian cancer, and leukaemia. | [18] |
| Porous silica CaP | 5-fluorouracil | Mammary tumors | [8,20] |
| NGO | SN38 | Colon cancer | [31,32,33,34,35,36] |
| Carboxylate NDs | Purvalanol and 4-hydroxytamoxitan | Liver and breast cancer | [40,41,42] |
| Single-walled carbon nanotubes (SWNTs)-polyethylene glycol (PEG), NGO-PEG and MSNPs-GO-chitosan (CHI) | Doxorubicin | Leukaemia, breast cancer, gastric cancer, head and neck cancer, Hodgkin’s lymphoma, liver cancer, kidney cancer, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thyroid cancer, bladder cancer, uterine sarcoma. | [53,54,55] |
| NDs-NaCl | HT-29 colorectal cancer cells. | [43] | |
| Gold NPs | Paclitaxel | Breast, lung, and pancreatic cancer. | [49] |